Literature DB >> 25025002

Atypical femoral fracture combined with osteonecrosis of jaw during osteoporosis treatment with bisphosphonate.

Yougun Won1, Joon-Ryul Lim2, Young-Hwan Kim2, Hyung-Keun Song3, Kyu Hyun Yang2.   

Abstract

Bisphosphonate, a potent anti-resorptive agent, is generally accepted as a safe, effective, well tolerated treatment for postmenopausal osteoporosis. Atypical femoral fracture (AFF) and bisphosphonate related osteonecrosis of jaw (BRONJ) are the increasing morbidities in patients treated with long term bisphosphonate. Pathogenic mechanisms of AFF and BRONJ are not fully identified and not identical. We report a case of BRONJ followed by AFF and its nonunion in a 67-year-old woman patient receiving an oral bisphosphonate during 7 years for the treatment of osteoporosis.

Entities:  

Keywords:  Atypical femoral fracture; Bisphosphonate

Year:  2014        PMID: 25025002      PMCID: PMC4075270          DOI: 10.11005/jbm.2014.21.2.155

Source DB:  PubMed          Journal:  J Bone Metab        ISSN: 2287-6375


INTRODUCTION

Bisphosphonate, a potent anti-resorptive agent, is generally accepted as a safe, effective, well tolerated treatment for postmenopausal osteoporosis. Although the short-term safety and the efficacy of these drugs have been investigated and documented, an increasing number of recent reports draw attention to the possible correlation between long-term bisphosphonate therapy and the occurrence of morbidities mediated by inhibition of osteoclast function serves to decrease resorption.[1] Recent reports have noted atypical femoral fractures (AFF) and bisphosphonate related osteonecrosis of jaw (BRONJ) are the increasing morbidity in patients who have undergone long-term bisphosphonate therapy for osteoporosis. [2,3,4,5,6,7] Pathogenic mechanisms of AFF and BRONJ are not identified and not identical. We experienced a rare case of BRONJ followed by AFF and its nonunion in a same patient who was treated by long-term bisphosphonate administration for osteoporosis.

CASE

A 67-year-old woman was diagnosed oseteoporosis and treated with oral Risedronate (150 mg/month for 2 years), Ibandronate (150 mg/month for 2 years) and Alendronate (70 mg/week for 3 years) for 7 years. She presented with sudden developed right hip pain despite no evidence of definite trauma. On the radiograph, transverse, noncomminuted subtrochanteric fracture with medical beak was noted. She was treated with closed reduction using long proximal femoral nail (Long Gamma-3 nail, Stryker) in the regional hospital (Fig. 1). Osteoporosis treatment has been discontinued. But from 6 months after the surgery she discontinued the schedule of our out-patient department. After three years of operation, she showed up at our out-patient department with pain in the right hip joint while walking despite no evidence of trauma. On the radiograph, nonunion of subtrochanteric fracture and breakage of long Gamma-3 nail was noticed (Fig. 2). Her height was 145 cm, body weight 55 kg, and body mass index (BMI) 26.1 kg/m2. The bone mineral density (BMD) of lumbar spine measured by dual energy X-ray absorptiometry (Discovery™, Hologic, Bedford, MA, USA) was 0.490 g/cm2, of which the T score was -3.6 and the Z score -1.2. The levels of serum calcium and phosphorus were 9.1 mg/dL (normal 8.6-10.0 mg/dL) and 4.5 mg/dL (normal 2.8-4.5 mg/dL), respectively. The serum C-terminal telopeptides of type I collagen (CTx) and urinary N-terminal telopeptides of type I collagen (NTx) levels measured by enzyme-linked immunosorbent assay (ELISA) were 55.7 nmoL bone collagen equivalents (BCE)/mmoL Cr (normal 6.0-125.7 nmoL BCE/mmoL Cr) and 0.26 ng/mL (normal 0.11-1.00 ng/mL). We removed the broken nail and exchanged to cephalomedullary nailing and autogenous iliac bone graft was done (Zimmer Natural Nail Cephalomedullary nail, Zimmer). We performed osteotomy at lateral cortex below the lag screw to making a notch for sliding (Fig. 3). After the revision operation, she was treated with daily subcutaneous injection of teriparatide (recombinant human parathyroid hormone 1-34) at a dose of 20 µg per day and her symptom resolved gradually for 6 months. She underwent outpatient follow up of dental clinic due to extraction of the mandibular right lateral incisor, right central incisor, left central incisor 1 year before visit to our outpatients department (OPD) clinic, following which the extraction socket never healed and pain and pus discharge for 2 months (Fig. 4). Oral antibiotics treatment and local debridement were ineffective. Sequestrectomy of mandible and incision and drainage of submental abscess was done. Intravenous antibiotics for 2 weeks and oral antibiotics for 10 weeks were administrated postoperatively. No more abscess drainage oral cavity and no more pain was complaint. BRONJ was diagnosed at 9 years after the osteoporosis treatment.
Fig. 1

(A) Preoperative radiograph shows subtrochanteric fracture of left femur: Transverse fracture with medial beak were noticed. (B) Postoperative radiograph after the initial operation.

Fig. 2

Nonunion and hardware failure developed at seven months after the operation.

Fig. 3

One year after hardware exchange and auto iliac bone graft for nonunion and hardware breakage. Lateral cortex osteotomy was performed at lateral cortex for sliding (arrow).

Fig. 4

(A) The dental panoramic view demonstrates osseous sclerosis (arrow) and radiolucent lesion with irregular margin on the mandible. (B) Clinical photo of extracted socket with ulceration. (C) The dental panoramic view after sequestrectomy.

DISCUSSION

Bisphosphonate is the most widely prescribing agent for treating osteoporosis. As one of the strong bone resorption inhibitors, it reduces the risks of major fractures in females with osteoporosis. However, many reports have suggested that long-term use of bisphosphonate is associated with AFF or BRONJ.[2,3,8,9] The patient of this case was treated with oral bisphosphonate for 7 years and discontinued as AFF was considered. Park-Wyllie et al.[10] reported that bisphosphonate treatment of more than five years was associated with an increased risk of atypical subtrochanteric or femoral shaft fractures. The incidence of AFF reported 3.2 to 5.9 cases per 100,000 person-years (with American Society for Bone and Mineral Research major criteria) and 113.1 cases per 100,000 cases per year for 8 to 9 years of use or 130 per 100,000 cases per year for 6 years of use.[9,10,11,12,13] Although incidence of BRONJ is small as 1/100,000-1/10,000 annually.[14] The risk of developing BRONJ associated with oral bisphosphonates appears to increase when the duration of therapy exceeds three years.[3] Many reports suggest that the use of intravenous bisphosphonates in cancer patients is associated with BRONJ.[3] But, with lower dose of oral bisphosphonate, BRONJ cases were also reported sporadically.[1,15,16] Association of Oral and Maxillofacial Surgeons reported local risk factor of BRONJ as 1) Extractions, 2) Dental implant placement, 3) Periapical surgery, 4) Periodontal surgery involving osseous injury and suggest three months of drug discontinuation prior to elective dental invasive procedure reduces the risk of developing BRONJ.[3] A common pathogenesis of BRONJ and AFF explains that the Jaw bone and lateral cortex of subtrochanteric area of femur demand to endure higher mechanical stress than the other bones that are comparable. Since bone remodeling removes old or damaged bone and replaces it with new bone, the suppression of remodeling may reduce damage repair of continuous mechanical stress.[2,9,17] The pathogenesis of BRONJ explains in several ways 1) Depletion of first line immune cell in the oral cavity; γδ T cells.[18] 2) Inhibition of epithelial migration and capillary tube formation for neo-angiogenesis.[19] The pathogenesis of AFF differ from that of BRONJ explains in several ways 1) Reduced heterogenecity, which reduces local stress and enhance energy dissipation, of organic matrix and mineral properties.[2] 2) high strain in the lateral cortex of the subtrochanteric area during various stage of gait cycle, especially in single stance phase. However, the current level of evidence of exact pathophysiology does not fully support relationship between AFF and BRONJ. We experienced a rare case of AFF followed by BRONJ related to long-term use of oral bisphosphonate therapy for osteoporosis who have 2 year of drug holidays in an elderly patient. When AFF was noticed, it is crucial for remind that a AFF can be a high risk factor of development of BRONJ and patients education for BRONJ should be considered, as senile patient have much chance for all invasive dental procedures.
  19 in total

1.  American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update.

Authors:  Salvatore L Ruggiero; Thomas B Dodson; Leon A Assael; Regina Landesberg; Robert E Marx; Bhoomi Mehrotra
Journal:  J Oral Maxillofac Surg       Date:  2009-05       Impact factor: 1.895

Review 2.  Osteonecrosis of the jaw: who gets it, and why?

Authors:  Ian R Reid
Journal:  Bone       Date:  2008-10-07       Impact factor: 4.398

Review 3.  Atypical femoral fractures: what do we know about them?: AAOS Exhibit Selection.

Authors:  Aasis Unnanuntana; Anas Saleh; Kofi A Mensah; John P Kleimeyer; Joseph M Lane
Journal:  J Bone Joint Surg Am       Date:  2013-01-16       Impact factor: 5.284

4.  Osteonecrosis of the jaws associated with the use of bisphosphonates. Discussion over 52 cases.

Authors:  H A Almăşan; Mihaela Băciuţ; H Rotaru; S Bran; Oana Cristina Almăşan; G Băciuţ
Journal:  Rom J Morphol Embryol       Date:  2011       Impact factor: 1.033

5.  Bisphosphonates and oral cavity avascular bone necrosis: a review of twelve cases.

Authors:  Nello Salesi; Roberto Pistilli; Vincenzo Marcelli; Flavio Andrea Govoni; Fabrizio Bozza; Giandominik Bossone; Viola Venturelli; Barbara Di Cocco; Umberto Pacetti; Alida Ciorra; Concetta Di Fonso; Enrico Cortesi; Enzo Veltri; Aldo Vecchione
Journal:  Anticancer Res       Date:  2006 Jul-Aug       Impact factor: 2.480

Review 6.  Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studies.

Authors:  Andrea Giusti; Neveen A T Hamdy; Socrates E Papapoulos
Journal:  Bone       Date:  2010-05-20       Impact factor: 4.398

Review 7.  Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research.

Authors:  Elizabeth Shane; David Burr; Bo Abrahamsen; Robert A Adler; Thomas D Brown; Angela M Cheung; Felicia Cosman; Jeffrey R Curtis; Richard Dell; David W Dempster; Peter R Ebeling; Thomas A Einhorn; Harry K Genant; Piet Geusens; Klaus Klaushofer; Joseph M Lane; Fergus McKiernan; Ross McKinney; Alvin Ng; Jeri Nieves; Regis O'Keefe; Socrates Papapoulos; Tet Sen Howe; Marjolein C H van der Meulen; Robert S Weinstein; Michael P Whyte
Journal:  J Bone Miner Res       Date:  2013-10-01       Impact factor: 6.741

Review 8.  A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.

Authors:  Michael Pazianas; Paul Miller; William A Blumentals; Myriam Bernal; Prajesh Kothawala
Journal:  Clin Ther       Date:  2007-08       Impact factor: 3.393

9.  Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.

Authors:  Sundeep Khosla; David Burr; Jane Cauley; David W Dempster; Peter R Ebeling; Dieter Felsenberg; Robert F Gagel; Vincente Gilsanz; Theresa Guise; Sreenivas Koka; Laurie K McCauley; Joan McGowan; Marc D McKee; Suresh Mohla; David G Pendrys; Lawrence G Raisz; Salvatore L Ruggiero; David M Shafer; Lillian Shum; Stuart L Silverman; Catherine H Van Poznak; Nelson Watts; Sook-Bin Woo; Elizabeth Shane
Journal:  J Bone Miner Res       Date:  2007-10       Impact factor: 6.741

Review 10.  Do bisphosphonates cause femoral insufficiency fractures?

Authors:  Andreas Seraphim; Nawfal Al-Hadithy; Simon C Mordecai; Shafic Al-Nammari
Journal:  J Orthop Traumatol       Date:  2012-08-01
View more
  6 in total

1.  Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates.

Authors:  A Sánchez; R Blanco
Journal:  Osteoporos Int       Date:  2016-11-20       Impact factor: 4.507

2.  Artemisia annua extract prevents ovariectomy-induced bone loss by blocking receptor activator of nuclear factor kappa-B ligand-induced differentiation of osteoclasts.

Authors:  Sun Kyoung Lee; Hyungkeun Kim; Junhee Park; Hyun-Jeong Kim; Ki Rim Kim; Seung Hwa Son; Kwang-Kyun Park; Won-Yoon Chung
Journal:  Sci Rep       Date:  2017-12-11       Impact factor: 4.379

3.  Paget's Disease: Skeletal Manifestations and Effect of Bisphosphonates.

Authors:  Ho Kang; Young-Chang Park; Kyu Hyun Yang
Journal:  J Bone Metab       Date:  2017-05-31

4.  Oral Bisphosphonate Induced Recurrent Osteonecrosis of Jaw with Atypical Femoral Fracture and Subsequent Mandible Fracture in the Same Patient: A Case Report.

Authors:  Ameet Pispati; Varun Pandey; Roopak Patel
Journal:  J Orthop Case Rep       Date:  2018 May-Jun

5.  Osteonecrosis of the Jaw and Bilateral Atypical Femoral Fracture Both Occurring During Treatment for Osteoporosis: A Case Report.

Authors:  Edelissa Payumo; Beinjerinck Ivan Cudal; Thelma Crisostomo
Journal:  J ASEAN Fed Endocr Soc       Date:  2018-09-12

6.  Prevalence and Risk Factors of Atypical Femoral Fracture Bone Scintigraphic Feature in Patients Experiencing Bisphosphonate-Related Osteonecrosis of the Jaw.

Authors:  Chang-Hee Lee; Seung Hyun Son; Chae Moon Hong; Ju Hye Jeong; Shin Young Jeong; Sang-Woo Lee; Jaetae Lee; Tae-Geon Kwon; Byeong-Cheol Ahn
Journal:  Nucl Med Mol Imaging       Date:  2018-07-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.